NZ751414A - Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof - Google Patents
Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereofInfo
- Publication number
- NZ751414A NZ751414A NZ751414A NZ75141417A NZ751414A NZ 751414 A NZ751414 A NZ 751414A NZ 751414 A NZ751414 A NZ 751414A NZ 75141417 A NZ75141417 A NZ 75141417A NZ 751414 A NZ751414 A NZ 751414A
- Authority
- NZ
- New Zealand
- Prior art keywords
- bcl
- antibody
- inhibitor
- combination
- mor00208
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16196184 | 2016-10-28 | ||
| PCT/EP2017/077654 WO2018078123A1 (en) | 2016-10-28 | 2017-10-27 | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ751414A true NZ751414A (en) | 2025-10-31 |
Family
ID=57218739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ751414A NZ751414A (en) | 2016-10-28 | 2017-10-27 | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US12358983B2 (enExample) |
| EP (2) | EP3532098B1 (enExample) |
| JP (3) | JP7094950B2 (enExample) |
| KR (2) | KR20230028571A (enExample) |
| CN (2) | CN118045175A (enExample) |
| AU (2) | AU2017348624B2 (enExample) |
| BR (1) | BR112019008244A2 (enExample) |
| CA (1) | CA3037246A1 (enExample) |
| CY (1) | CY1124648T1 (enExample) |
| DK (1) | DK3532098T3 (enExample) |
| ES (1) | ES2871574T3 (enExample) |
| HR (1) | HRP20210838T1 (enExample) |
| HU (1) | HUE054496T2 (enExample) |
| IL (3) | IL266216B2 (enExample) |
| LT (1) | LT3532098T (enExample) |
| MX (2) | MX2019004942A (enExample) |
| NZ (1) | NZ751414A (enExample) |
| PL (1) | PL3532098T3 (enExample) |
| PT (1) | PT3532098T (enExample) |
| RS (1) | RS62036B1 (enExample) |
| RU (1) | RU2756405C2 (enExample) |
| SG (1) | SG10202104036QA (enExample) |
| SI (1) | SI3532098T1 (enExample) |
| SM (1) | SMT202100347T1 (enExample) |
| WO (1) | WO2018078123A1 (enExample) |
| ZA (1) | ZA201903302B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3337506B1 (en) | 2015-08-21 | 2021-07-21 | MorphoSys AG | Combinations and uses thereof |
| JP7094950B2 (ja) | 2016-10-28 | 2022-07-04 | モルフォシス・アーゲー | 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用 |
| DK3630177T5 (da) | 2017-05-31 | 2024-09-02 | Morphosys Ag | Behandlingsparadigme til et anti-cd19-antistof og venetoclax-kombinationsbehandling |
| GB201809746D0 (en) | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
| US20210322564A1 (en) * | 2018-08-31 | 2021-10-21 | Adc Therapeutics Sa | Combination therapy |
| WO2021084064A1 (en) * | 2019-10-31 | 2021-05-06 | Morphosys Ag | Sequential anti-cd19 therapy |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60500673A (ja) | 1983-03-08 | 1985-05-09 | コモンウエルス セラム ラボラトリ−ズ コミツシヨン | 抗原活性を有するアミノ酸配列 |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| CN1592645A (zh) | 2000-09-18 | 2005-03-09 | 拜奥根Idec公司 | 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法 |
| AU2002357060A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| US7109304B2 (en) | 2003-07-31 | 2006-09-19 | Immunomedics, Inc. | Humanized anti-CD19 antibodies |
| EP1899379B1 (en) | 2005-06-20 | 2018-04-11 | E. R. Squibb & Sons, L.L.C. | Cd19 antibodies and their uses |
| CA2635623C (en) | 2005-12-30 | 2015-02-17 | Michael Super | Anti-cd19 antibodies with reduced immunogenicity |
| PT2059536E (pt) | 2006-08-14 | 2014-04-14 | Xencor Inc | Anticorpos otimizados que visam cd19 |
| ATE552204T1 (de) | 2006-08-15 | 2012-04-15 | Hydralift Amclyde Inc | Direkt wirkender einzelscheiben-aktiv/passiv- hubkompensator |
| US8323653B2 (en) | 2006-09-08 | 2012-12-04 | Medimmune, Llc | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| SG166093A1 (en) | 2006-09-22 | 2010-11-29 | Pharmacyclics Inc | Inhibitors of brutonæs tyrosine kinase |
| CA2693053C (en) | 2007-05-30 | 2021-01-05 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| US7968687B2 (en) | 2007-10-19 | 2011-06-28 | Seattle Genetics, Inc. | CD19 binding agents and uses thereof |
| US20100128586A1 (en) | 2008-11-25 | 2010-05-27 | Mediatek Inc. | Method and apparatus for accessing data from disc with linking area |
| EP2398829A2 (en) | 2009-02-23 | 2011-12-28 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| AU2010263272C1 (en) | 2009-06-24 | 2016-02-11 | The Feinstein Institute For Medical Research | Method for treating chronic lymphocytic leukemia |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| NZ717373A (en) | 2010-06-03 | 2017-11-24 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| US8549399B2 (en) | 2011-01-18 | 2013-10-01 | Apple Inc. | Identifying a selection of content in a structured document |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| SMT202200160T1 (it) | 2011-08-16 | 2022-05-12 | Morphosys Ag | Terapia in combinazione con un anticorpo anti-cd19 e un analogo delle purine |
| WO2013024097A1 (en) | 2011-08-16 | 2013-02-21 | Morphosys Ag | Combination therapy with an anti - cd19 antibody and a nitrogen mustard |
| CA2929918C (en) * | 2013-12-05 | 2018-01-23 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
| ES2818110T3 (es) * | 2014-02-28 | 2021-04-09 | Merck Sharp & Dohme | Tratamiento del cáncer con una combinación que comprende dinaciclib |
| KR102487608B1 (ko) * | 2014-04-07 | 2023-01-12 | 노파르티스 아게 | 항-cd19 키메라 항원 수용체를 사용한 암의 치료 |
| WO2015195498A1 (en) | 2014-06-16 | 2015-12-23 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (cll) |
| CN107106610A (zh) | 2014-10-20 | 2017-08-29 | 朱诺治疗学股份有限公司 | 用于过继细胞治疗中的给药的组合物和方法 |
| HK1247619A1 (zh) * | 2015-02-12 | 2018-09-28 | Seattle Genetics, Inc. | 使用抗 dc 19抗体–药物共轭物及长春新硷的联合治疗 |
| HK1251152B (en) | 2015-05-26 | 2020-04-24 | Morphosys Ag | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof |
| CN107847600B (zh) | 2015-05-26 | 2021-09-03 | 豪夫迈·罗氏有限公司 | 抗CD20抗体与Bcl-2抑制剂和MDM2抑制剂的组合疗法 |
| BR112017028530A2 (pt) | 2015-07-02 | 2018-08-28 | Celgene Corp | terapia combinada para tratamento de cânceres hematológicos e tumores sólidos |
| EP3337506B1 (en) | 2015-08-21 | 2021-07-21 | MorphoSys AG | Combinations and uses thereof |
| ES2878156T3 (es) | 2016-05-30 | 2021-11-18 | Morphosys Ag | Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes |
| MA45450B1 (fr) | 2016-06-27 | 2021-04-30 | Morphosys Ag | Formulations d'anticorps anti-cd19 |
| JP7094950B2 (ja) | 2016-10-28 | 2022-07-04 | モルフォシス・アーゲー | 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用 |
| DK3630177T5 (da) * | 2017-05-31 | 2024-09-02 | Morphosys Ag | Behandlingsparadigme til et anti-cd19-antistof og venetoclax-kombinationsbehandling |
| US20210292410A1 (en) | 2017-12-07 | 2021-09-23 | Morphosys Ag | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| WO2020225196A1 (en) | 2019-05-03 | 2020-11-12 | Morphosys Ag | Anti-cd19 therapy in patients having a limited number of nk cells |
| IL292213A (en) | 2019-10-31 | 2022-06-01 | Morphosys Ag | Combination anti-tumor therapy including anti-cd19 antibody and gamma delta t cells |
| IL317199A (en) | 2019-10-31 | 2025-01-01 | Morphosys Ag | Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma |
| WO2021084064A1 (en) | 2019-10-31 | 2021-05-06 | Morphosys Ag | Sequential anti-cd19 therapy |
| KR20230030636A (ko) | 2020-06-22 | 2023-03-06 | 모르포시스 아게 | 항-CD19 항체, 및 SIRPα-CD47 선천성 면역 체크포인트를 차단하는 폴리펩티드를 포함하는 항-종양 조합 요법 |
| TW202237184A (zh) | 2020-12-04 | 2022-10-01 | 德商莫菲西斯公司 | 抗cd19組合療法 |
| KR20240131370A (ko) | 2021-12-22 | 2024-08-30 | 인사이트 코포레이션 | 항-cd19 항체 요법을 위한 치료 패러다임 |
-
2017
- 2017-10-27 JP JP2019522273A patent/JP7094950B2/ja active Active
- 2017-10-27 RS RS20210792A patent/RS62036B1/sr unknown
- 2017-10-27 IL IL266216A patent/IL266216B2/en unknown
- 2017-10-27 RU RU2019113370A patent/RU2756405C2/ru active
- 2017-10-27 EP EP17797564.6A patent/EP3532098B1/en active Active
- 2017-10-27 CN CN202410183851.8A patent/CN118045175A/zh active Pending
- 2017-10-27 ES ES17797564T patent/ES2871574T3/es active Active
- 2017-10-27 IL IL320372A patent/IL320372A/en unknown
- 2017-10-27 AU AU2017348624A patent/AU2017348624B2/en active Active
- 2017-10-27 EP EP21165598.0A patent/EP3903821A1/en active Pending
- 2017-10-27 US US16/342,645 patent/US12358983B2/en active Active
- 2017-10-27 KR KR1020237005018A patent/KR20230028571A/ko not_active Ceased
- 2017-10-27 BR BR112019008244-1A patent/BR112019008244A2/pt unknown
- 2017-10-27 HU HUE17797564A patent/HUE054496T2/hu unknown
- 2017-10-27 SM SM20210347T patent/SMT202100347T1/it unknown
- 2017-10-27 MX MX2019004942A patent/MX2019004942A/es unknown
- 2017-10-27 SG SG10202104036QA patent/SG10202104036QA/en unknown
- 2017-10-27 CA CA3037246A patent/CA3037246A1/en active Pending
- 2017-10-27 IL IL301786A patent/IL301786B2/en unknown
- 2017-10-27 LT LTEP17797564.6T patent/LT3532098T/lt unknown
- 2017-10-27 SI SI201730811T patent/SI3532098T1/sl unknown
- 2017-10-27 PL PL17797564T patent/PL3532098T3/pl unknown
- 2017-10-27 HR HRP20210838TT patent/HRP20210838T1/hr unknown
- 2017-10-27 NZ NZ751414A patent/NZ751414A/en unknown
- 2017-10-27 CN CN201780067047.1A patent/CN109890418B/zh active Active
- 2017-10-27 DK DK17797564.6T patent/DK3532098T3/da active
- 2017-10-27 WO PCT/EP2017/077654 patent/WO2018078123A1/en not_active Ceased
- 2017-10-27 KR KR1020197012532A patent/KR102500868B1/ko active Active
- 2017-10-27 PT PT177975646T patent/PT3532098T/pt unknown
-
2019
- 2019-04-26 MX MX2022016270A patent/MX2022016270A/es unknown
- 2019-05-24 ZA ZA2019/03302A patent/ZA201903302B/en unknown
-
2021
- 2021-06-10 CY CY20211100512T patent/CY1124648T1/el unknown
-
2022
- 2022-06-22 JP JP2022100006A patent/JP2022137089A/ja active Pending
-
2024
- 2024-08-01 JP JP2024125584A patent/JP2024167208A/ja active Pending
- 2024-12-23 AU AU2024287178A patent/AU2024287178A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ751414A (en) | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof | |
| MX2022006154A (es) | Combinaciones y sus usos. | |
| ZA202107931B (en) | Anti-tau antibodies and methods of use | |
| WO2016062722A8 (en) | Combination | |
| CY1122298T1 (el) | Συνδυασμος αντισωματος anτι-cd19 και αναστολεα τυροσινης κινασης toy bruton και χρησεις του | |
| MX2024000300A (es) | Anticuerpos antitau y metodos de uso. | |
| PH12017501318B1 (en) | Anti-transthyretin antibodies | |
| MX2019015516A (es) | Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer. | |
| IL271266A (en) | Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia | |
| CY1125148T1 (el) | Θεραπεια συνδυασμου με αντι-cd19 αντισωμα και αναλογο πουρινης | |
| AR099619A1 (es) | Polímero viscosificante para el tratamiento de una formación subterránea | |
| MX2019006330A (es) | Anticuerpos anti-tau y metodos de uso. | |
| WO2015153513A8 (en) | Anti-ox40 antibodies and methods of use | |
| EP3721910A3 (en) | Radiation activated gels that release fluids and assemblies containing the same | |
| MX2019005401A (es) | Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma. | |
| CY1125122T1 (el) | Θεραπεια συνδυασμου me anti-cd19 αντισωμα και μουσταρδα αζωτου | |
| PH12018500887A1 (en) | Anti-htra1 antibodies and methods of use thereof | |
| IL263165A (en) | Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment | |
| MX2019011423A (es) | Metodos de tratamiento de enfermedades neurodegenerativas. | |
| MY188849A (en) | Combination therapy of an anti cd20 antibody with a bcl-2 inhibitor and a mdm2 inhibitor | |
| MX2020002613A (es) | Accionador lineal de alta reduccion impulsado por correas. | |
| MX2018001737A (es) | Mecanismo de resistencia a inhibidores de bromodominio bet. | |
| MX2017015311A (es) | Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer. | |
| HK40079976A (en) | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma | |
| MY193688A (en) | Anti-transthyretin antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: INCYTE CORPORATION, US Effective date: 20241209 |